MUSTANG BIO (MBIO) Covered Calls

You can sell covered calls on MUSTANG BIO to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MBIO (prices last updated Mon 2:40 PM ET):

MUSTANG BIO (MBIO) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
4.69 -0.57 4.68 4.70 22K - 0.1B
Covered Calls For MUSTANG BIO (MBIO)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Nov 16 5 0.00 4.70 0.0% 0.0%
Dec 21 5 0.00 4.70 0.0% 0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.